20
Participants
Start Date
August 25, 2023
Primary Completion Date
December 15, 2025
Study Completion Date
December 15, 2025
AK104
AK104 15mg/kg intravenously(IV) every 3 weeks (Q3W), until progressive disease, unacceptable toxicity, completion of 2 years treatment or withdrawal of consent.
AK104+ Paclitaxel+Cisplatin or Carboplatin
AK104 (10 mg/kg) + paclitaxel (175 mg/m2)+ cisplatin (50 mg/m2) or carboplatin (AUC 4-5) , IV, Q3W, for up to 6 cycles, followed by maintenance therapy of AK104 10 mg/kg Q3W until disease progression, intolerable toxicity, withdrawal of consent, or completion of 2 years treatment.
RECRUITING
Liaoning Cancer Hospital & Insitut, Shenyang
RECRUITING
Tianjin medical university Cancer Institut & Hospital, Tianjin
NOT_YET_RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Clinical oncology school of Fujian Medical University, Fujian Cancer Hospital, Fuzhou
RECRUITING
Sun Yant-Sen Memorial Hospital, Guangzhou
NOT_YET_RECRUITING
The Fourth Hospital of Hebei Medical University, Shijiangzhuang
Lead Sponsor
Akeso
INDUSTRY